歐洲的臉部注射劑市場:2012年

歐洲的臉部注射劑市場:2012年 是由出版商Millennium Research Group在2011年12月所出版的。 這份英文市場調查報告書價格從美金6995起跳。

簡介

2011年，歐洲的主要國家(法國·德國·意大利·西班牙·英國)的美容處理用臉部注射劑的市場穩定成長。由於歐洲的消費者對美容·外觀的高度關注和企業對消費者的行銷·促銷活動，使更多的消費者接受臉部注射處理。

本報告提供歐洲的臉部注射劑市場現況與展望調查分析，治療種類與概要，各國市場背景，主要產品的功能，差異化特性，新產品概要，臨床實驗趨勢，領導品牌的競爭環境與市場佔有率，各國與各類產品的市場成長預測(∼2016年)等彙整資料，為您概述為以下內容。

摘要整理

第1章 臨床環境

• 背景
• 診斷和轉診模式
• 治療概要
  • 臉部注射治療
  • 治療方法的競爭
  • 新的競爭治療·技術
• 臨床指南
• 報銷指南
• 各國概要
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
    • 人口統計與經濟
    • 醫療制度
    • 法律制度
  • 製造·流通

第2章 產品

• 概要
• 肉毒桿菌毒素
  • 功能
  • 差異化特性
  • 新產品
• 皮下注射劑
  • 功能
  • 差異化特性
  • 新產品
• 新的技術

第3章 臨床實驗

• 完成的臨床實驗
• 持續中的臨床實驗

第4章 品牌及競爭分析

• 概要
  • 競爭概要
  • 更多的競爭環境
  • 市場佔有率
  • 近幾年的事項
• 肉毒桿菌毒素
  • 競爭概要
  • 更多的競爭環境
  • 目前市場佔有率
• 皮下注射劑
  • 競爭概要
  • 更多的競爭環境
  • 目前市場佔有率

第5章 市場預測

• 概要
  • 市場概要
  • 詳細的市場概要
• 肉毒桿菌毒素
  • 市場概要
  • 詳細的市場概要
• 皮下注射劑
  • 市場概要
  • 詳細的市場概要

附錄

圖表

目錄

Abstract

The European facial injectables market, comprising revenues from the sale of botulinum toxin (BTX) and dermal fillers - including hyaluronic acid (HA) and semi- and nonpermanent non-HA fillers - for cosmetic procedures in France, Germany, Italy, Spain, and the UK, continued to experience moderate growth through 2011. The high aesthetic focus of Europeans, combined with end-consumer marketing and significant promotions provided by manufacturers, enticed more consumers to get facial injectable treatments. Additionally, growth will be driven by demand from a broadening patient demographic; younger women are seeking facial injectable treatments as a preventative measure against symptoms of aging, and more men are becoming increasingly accepting of undergoing facial injectable procedures. Economic turmoil, especially in weak economies like Italy and Spain, will continue to hinder the number of consumers willing to spend money on these cosmetic and mainly elective procedures through 2016; however, disposable incomes will increase as the economy gradually recovers toward the end of the forecast period; in turn, consumer demand for antiaging and antiwrinkle removal treatments will rise. Some patients and physicians are, however, still concerned about the safety and side effects of facial injectable products, which will continue to limit the European facial injectable market. This is especially the case for semi- and nonpermanent non-HA fillers, which have been negatively affected due to product recalls and adverse patient reactions to some products in this segment. Furthermore, competition from alternative treatments (e.g. lasers and cosmeceuticals) and emerging technologies (e.g. platelet rich plasma or autologous skin cell/fat fillers) will represent potential threats to revenues gained by facial injectables through 2016. Despite this, the facial injectable market will continue to grow robustly, attracting new entrants all vying for greater revenues that will create negative pressures on average selling prices (ASPs) especially during the beginning of the forecast period. As a result of the aforementioned mentioned factors, the European facial injectable market will see strong growth through 2016.

METHODOLOGY

RESEARCH METHODOLOGY

This report uses a number of methodologies to gather and present data and analysis. At the outset, a large survey of secondary sources is conducted. These sources act as the basis for the primary research stage, which builds and enhances the quantitative and qualitative attributes of the early research.

Secondary sources include

• Government sources:
  • Securities and Exchange Commission filings
  • UK National Health Service
  • Spain National Statistics Institute
  • Italy National Institute of Statistics
  • US Census Bureau
  • Food and Drug Administration and patent filings
  • National Center for Health Statistics data
• Aesthetic (facial injectable) companies:
  • Annual reports, product brochures, corporate profiles, etc.
• Internal databases and reports:
  • Previous reports on similar/related sources
• General Internet searches, medical literature, and newspaper/magazine searches:
  • Identifying various centers of specialization and articles that might provide leads for primary research

The secondary research stage builds the foundation for the primary research.

The primary research methodology has four steps:

Step 1: The first step involves an impartial scan of all the information gathered during the secondary research stage to determine its utility based on the specific requirements of this report. Each piece of information is either discarded or marked as high- or low-priority and then organized appropriately as determined by the structure and sectioning of the report.

Step 2: At this stage, early assumptions are formed as to the implications of the information for the various facial injectable market segments. These assumptions are then used to determine hypotheses using both inductive and deductive approaches. On the quantitative front, these hypotheses result in full historical and projected market data sets (market sizes - unit sales, average selling prices [ASPs], and revenues - as well as market shares).

Step 3: At this stage, the research is in position for its most important primary phase - expert interviews. Throughout the secondary research phase, industry and medical experts are identified. These experts are then contacted by telephone and asked to participate in interviews on recent trends and developments in the industry. Interviews are either conducted at the time of the initial call or scheduled at the convenience of the expert. Interview questions are tailored to the expertise of each particular interviewee, although in most cases, the most important questions are asked of all experts.

The questions are largely based on the assumptions and hypotheses developed in Step 2, which are then augmented, discarded, or adjusted based on the views and positions put forth. Attempts are made, whenever possible, to cross-check the views of various experts against each other and to reach positions of consensus on issues and market numbers.

Step 4: The final stage of primary research involves individual and group analysis by Millennium Research Group. All research results are assessed and cross-checked thoroughly to determine their validity, relevance, and weight. From this process, qualitative conclusions are reached and data points finalized.

MARKETRACK METHODOLOGY

Millennium Research Group's Facial Aesthetics Marketrack methodology involves recruiting medical personnel responsible for the management or injection of facial injectables (e.g. plastic surgeons, dermatologists, office managers of aesthetic clinics, and other aesthetic practitioners) to participate by providing procedure volumes, device usage data, and brand-level pricing information on an ongoing basis.

Key benefits of Marketrack data collection include

• a dedicated team of in-house Marketrack researchers, ensuring high-quality data gathering, verification, and analysis;
• an extensive network of facilities (dermatology, plastic surgery, and medispas) that recognize the Marketrack brand and engage in ongoing research; and
• regular client feedback on all projects, leading to continuous improvements in data quality, presentation, usability, and methodology.

FORECAST METHODOLOGY

In addition to the research methodology outlined above, the following “bottom-up” methodology is used to develop forecast assumptions for the report.

A comprehensive breakdown of various facial injectable procedures and unit sales is prepared using data from several sources, including professional associations, government statistics, and private research/media sources. Industry experts and practitioners are consulted to ensure accuracy and verify observed trends. As a cross-check, total industry revenues available through annual reports and other sources are compared against modeled industry revenues.

Using the best estimates of industry experts, practitioners, private research/media sources, and inhouse experts, year-by-year growth rates and ASPs are applied individually to each subcategory to derive forecasts. These estimates are cross-checked by industry experts (marketing managers, product managers, CEOs, etc.) and further refined.

Overall findings are compared against market and procedure forecasts published by other sources to ensure reasonable estimates.

Companies mentioned in this report:

• aap bio implants
• Adoderm
• Aesthetic Factors
• Allergan
• Anika Therapeutics
• Anteis
• AQTIS Medical
• Biocompatibles
• BioPolymer
• Contura
• Croma-Pharma
• Fibrocell Science
• Fidia Farmaceutici
• Galderma
• Ipsen
• Kaylight
• Laboratoires CosmoScience
• Laboratoires FILORGA
• Laboratoires Genevrier
• Laboratoires ORGEV
• Laboratoires Pierre Fabre
• Laboratoires TEOXANE
• Laboratoires VIVACY
• LCA Pharmaceutical
• MD Skin Solutions
• Mentor (a Johnson & Johnson company)
• Merz Pharmaceuticals
• Prollenium Medical Technologies
• Q-Med (recently acquired by Galderma)
• Revance Therapeutics
• Sanofi
• Solstice Neurosciences
• Stiefel Laboratories (a GlaxoSmithKline company)
• Valeant Pharmaceuticals

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

1.0. CLINICAL LANDSCAPE

• 1.1. Background
• 1.2. Diagnosis and Referral Patterns
• 1.3. Procedure Overview
  • 1.3.1. Facial Injectable Procedures
  • 1.3.2. Competing Treatments
  • 1.3.3. Emerging Competing Treatments and Technologies
• 1.4. Clinical Guidelines
• 1.5. Reimbursement Guidelines
• 1.6. Country Overviews
  • 1.6.1. France
    • 1.6.1.1. Demographics and Economy
    • 1.6.1.2. Health Care System
    • 1.6.1.3. Regulatory Environment
  • 1.6.2. Germany
    • 1.6.2.1. Demographics and Economy
    • 1.6.2.2. Health Care System
    • 1.6.2.3. Regulatory Environment
  • 1.6.3. Italy
    • 1.6.3.1. Demographics and Economy
    • 1.6.3.2. Health Care System
    • 1.6.3.3. Regulatory Environment
  • 1.6.4. Spain
    • 1.6.4.1. Demographics and Economy
    • 1.6.4.2. Health Care System
    • 1.6.4.3. Regulatory Environment
  • 1.6.5. UK
    • 1.6.5.1. Demographics and Economy
    • 1.6.5.2. Health Care System
    • 1.6.5.3. Regulatory Environment
  • 1.6.6. Manufacturing and Distribution

2.0. PRODUCTS

• 2.1. Overview
  • 2.1.1. Products Covered
  • 2.1.2. Differentiating Features
• 2.2. Botulinum Toxins
  • 2.2.1. Functions
  • 2.2.2. Labeled Indications
  • 2.2.3. Emerging Products
• 2.3. Dermal Fillers
  • 2.3.1. Functions
    • 2.3.1.1. Hyaluronic Acid Fillers
    • 2.3.1.2. Other Dermal Fillers
  • 2.3.2. Differentiating Features
  • 2.3.3. Labeled Indications
  • 2.3.4. Emerging Products
• 2.4. Emerging Technologies

3.0. CLINICAL TRIALS

• 3.1. Completed Clinical Trials
• 3.2. Ongoing Clinical Trials

4.0. BRANDS AND COMPETITIVE ANALYSIS

• 4.1. Overview
  • 4.1.1. Competitive Snapshot
  • 4.1.2. Detailed Competitive Landscape
  • 4.1.3. Market Shares
  • 4.1.4. Recent Events
• 4.2. Botulinum Toxin Market
  • 4.2.1. Competitive Snapshot
  • 4.2.2. Detailed Competitive Landscape
  • 4.2.3. Current Market Shares
• 4.3. Dermal Filler Market
  • 4.3.1. Competitive Snapshot
  • 4.3.2. Detailed Competitive Landscape
  • 4.3.3. Current Market Shares

5.0. MARKET OUTLOOK

• 5.1. Overview
  • 5.1.1. Market Snapshot
  • 5.1.2. Detailed Market Overview
• 5.2. Botulinum Toxin Market
  • 5.2.1. Market Snapshot
  • 5.2.2. Detailed Market Overview
• 5.3. Dermal Filler Market
  • 5.3.1. Market Snapshot
  • 5.3.2. Detailed Market Overview

APPENDIX A: METHODOLOGY

APPENDIX B: MRG ACRONYMS AND INITIALISMS

APPENDIX C: BIBLIOGRAPHY

LIST OF FIGURES AND TABLES

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

• Figure 1: Facial Injectable Market, by Country, Europe (US$), 2010 - 2016
• Table 1: Facial Injectable Market Landscape, Europe (US$), 2011 and 2016
• Table 2: Facial Injectable Market Leaders, by Product Type and Revenue, Europe, 2011
• Table 3: Most Promising Emerging Technologies in the Facial Injectable Market, Europe, 2011 - 2016
• Table 4: Expected Key Events in the Facial Injectable Market, Europe, 2012 - 2016
• Table 5: Factors Impacting the Facial Injectable Market, by Product Type, Europe, 2011 - 2016
• Table 6: Companies Mentioned in This Report
• Table 7: Key Report Updates, 2012

1.0 CLINICAL LANDSCAPE

• Table 8: Areas of the Face Commonly Treated with Facial Injectables
• Table 9: Common Facial Injectable Indications, by Product Type, Europe, 2011
• Table 10: Volume of Facial Injectable Product per Procedure, by Product
• Table 11: Competing Treatments, Europe, 2011
• Table 12: Facial Injectable Treatment Guidelines, by Product Type, Europe
• Table 13: Key Health and Economic Indicators, France, 2011
• Table 14: Key Health and Economic Indicators, Germany, 2011
• Table 15: Key Health and Economic Indicators, Italy, 2011
• Table 16: Key Health and Economic Indicators, Spain, 2011
• Table 17: Key Health and Economic Indicators, UK, 2011

2.0 PRODUCTS

• Table 18: Facial Injectable Market, by Product Type, Europe
• Table 19: Advantages and Disadvantages of Facial Injectables, by Product Type
• Table 20: BTX Functions, by Serotypes
• Table 21: Common Cosmetic BTX Products, Europe, 2011
• Table 22: Emerging Products in Development for the BTX Market, Europe, 2011 - 2016
• Table 23: Dermal Filler Functions, by Material and Product Features
• Table 24: Common HA Dermal Filler Products, Europe, 2011
• Table 25: Common Other Dermal Filler Products, Europe, 2011
• Table 26: Advantages and Disadvantages of Dermal Fillers, by Material and Product Features

3.0 CLINICAL TRIALS

• Table 27: Summary of NT 201 in Comparison with Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines (Head2Head)
• Table 28: Summary of Safety and Efficacy of Two Types of Botulinum Toxin Type A for the Treatment of Glabellar Lines
• Table 29: Summary of Safety and Effectiveness of Aquamid as Compared to Restylane for the Aesthetic Treatment of Nasolabial Folds
• Table 30: Summary of Safety and Efficacy of JUVEDERM Injectable Gel with Lidocaine
• Table 31: Summary of Solid State Hyaluronic Acid: A Novel Delivery System to Enable the Precise and Rapid Treatment of Fine and Deep Wrinkles
• Table 32: Summary of EMERVEL Classic Lidocaine Versus JUVEDERM Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds
• Table 33: Summary of JUVEBTX
• Table 34: Summary of Proof of Concept Study to Evaluate the Efficacy and Tolerability of Repeated Versus Single Treatment with Botulinum Toxin (VISTABEL) Treatment in Combination with a Hyaluronic Acid (JUVEDERM Ultra 2) in Patients with Glabellar Frown Lines
• Table 35: Summary of Volume Restoration of the Aging Midface with Sculptra Aesthetic

4.0 BRANDS AND COMPETITIVE ANALYSIS

• Table 36: Leading Competitors in the Facial Injectable Market, by Product Type, as a % of Total, Europe, 2011
• Table 37: Recent Events in the Facial Injectable Market, Europe, 2011
• Table 38: Leading Competitors in the BTX Market, by Country, as a % of Total, Europe, 2011
• Table 39: Leading Competitors in the Dermal Filler Market, by Country, as a % of Total, Europe, 2011
• Table 40: Leading Competitors in the Dermal Filler Market, by Material, as a % of Total, Europe, 2011

5.0 MARKET OUTLOOK

• Figure 2: Facial Injectable Market, by Product Type, Europe (US$), 2010 - 2016
• Table 41: Factors Impacting the Facial Injectable Market, by Product Type, Europe, 2011 - 2016
• Table 42: Facial Injectable Procedures, by Product Type, Europe, 2010 - 2016
• Table 43: Facial Injectable Procedures, by Country, Europe, 2010 - 2016
• Table 44: Facial Injectable Market, by Product Type, Europe (US$), 2010 - 2016
• Table 45: Facial Injectable Market, by Product Type, Europe (€ ), 2010 - 2016
• Table 46: Facial Injectable Market Growth, by Product Type, Europe, 2011 - 2016
• Table 47: Facial Injectable Market, by Product Type, as a % of Total, Europe, 2010 - 2016
• Table 48: Facial Injectable Market, by Country, Europe (US$), 2010 - 2016
• Table 49: Facial Injectable Market, by Country, Europe (€ and £), 2010 - 2016
• Table 50: Facial Injectable Market Growth, by Country, Europe, 2011 - 2016
• Table 51: Facial Injectable Market, by Country, as a % of Total, Europe, 2010 - 2016
• Figure 3: BTX Market, Europe (US$), 2010 - 2016
• Table 52: BTX Procedures, by Country, Europe, 2010 - 2016
• Table 53: BTX Market, by Country, Europe (US$), 2010 - 2016
• Table 54: BTX Market, by Country, Europe (€ and £), 2010 - 2016
• Table 55: BTX Market Growth, by Country, Europe, 2011 - 2016
• Table 56: BTX Market, by Country, as a % of Total, Europe, 2010 - 2016
• Figure 4: Dermal Filler Units, by Material, as a % of Total, Europe, 2011 and 2016
• Table 57: Dermal Filler Procedures, by Material, Europe, 2010 - 2016
• Table 58: Dermal Filler Procedures, by Country, Europe, 2010 - 2016
• Table 59: Dermal Filler Market, by Material, Europe (US$), 2010 - 2016
• Table 60: Dermal Filler Market, by Material, Europe (€ ), 2010 - 2016
• Table 61: Dermal Filler Market Growth, by Material, Europe, 2011 - 2016
• Table 62: Dermal Filler Market, by Material, as a % of Total, Europe, 2010 - 2016
• Table 63: Dermal Filler Market, by Country, Europe (US$), 2010 - 2016
• Table 64: Dermal Filler Market, by Country, Europe (€ and £), 2010 - 2016
• Table 65: Dermal Filler Market Growth, by Country, Europe, 2011 - 2016
• Table 66: Dermal Filler Market, by Country, as a % of Total, Europe, 2010 - 2016
• Table 67: Dermal Filler Market, by Country and Material, Europe (US$), 2010 - 2016
• Table 68: Dermal Filler Market, by Country and Material, Europe (€ and £), 2010 - 2016
• Table 69: HA Dermal Filler Market, by Country, Europe (US$), 2010 - 2016
• Table 70: HA Dermal Filler Market, by Country, Europe (€ and £), 2010 - 2016
• Table 71: HA Dermal Filler Market Growth, by Country, Europe, 2011 - 2016
• Table 72: HA Dermal Filler Market, by Country, as a % of Total, Europe, 2010 - 2016
• Table 73: Other Dermal Filler Market, by Country, Europe (US$), 2010 - 2016
• Table 74: Other Dermal Filler Market, by Country, Europe (€ and £), 2010 - 2016
• Table 75: Other Dermal Filler Market Growth, by Country, Europe, 2011 - 2016
• Table 76: Other Dermal Filler Market, by Country, as a % of Total, Europe, 2010 - 2016

APPENDIX A: METHODOLOGY

• Table 77: Average Currency Exchange Rates, 2011

APPENDIX B: MRG ACRONYMS AND INITIALISMS

• MRG Acronyms and Initialisms

APPENDIX C: BIBLIOGRAPHY

Press Release

預計2013年歐洲的臉部注射劑市場將恢復景氣，2016年呈2位數成長

相關商品